Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Seborrheic dermatitis Indication Strategy Report 2026: AHR, Trials and Deals
23 July 2026
2026 Seborrheic dermatitis strategy: epidemiology, AHR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Dyshidrotic eczema Indication Strategy Report 2026: IL-4Rα, Trials and Deals
23 July 2026
2026 Dyshidrotic eczema strategy: epidemiology, IL-4Rα biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Nummular dermatitis Indication Strategy Report 2026: IL-4Rα, Trials and Deals
23 July 2026
2026 Nummular dermatitis strategy: epidemiology, IL-4Rα biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
NUT carcinoma Indication Strategy Report 2026: BRD4, Trials and Deals
23 July 2026
2026 NUT carcinoma strategy: epidemiology, BRD4 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Acute promyelocytic leukemia Indication Strategy Report 2026: RARα, Trials and Deals
23 July 2026
2026 Acute promyelocytic leukemia strategy: epidemiology, RARα biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Solitary plasmacytoma Indication Strategy Report 2026: BCMA, Trials and Deals
23 July 2026
2026 Solitary plasmacytoma strategy: epidemiology, BCMA biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Plasmablastic lymphoma Indication Strategy Report 2026: CD38, Trials and Deals
23 July 2026
2026 Plasmablastic lymphoma strategy: epidemiology, CD38 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Extranodal NK/T-cell lymphoma Indication Strategy Report 2026: PD-1, Trials and Deals
23 July 2026
2026 Extranodal NK/T-cell lymphoma strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Adult T-cell leukemia/lymphoma Indication Strategy Report 2026: CCR4, Trials and Deals
23 July 2026
2026 Adult T-cell leukemia/lymphoma strategy: epidemiology, CCR4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hairy cell leukemia Indication Strategy Report 2026: BRAF, Trials and Deals
23 July 2026
2026 Hairy cell leukemia strategy: epidemiology, BRAF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Marginal zone lymphoma Indication Strategy Report 2026: BTK, Trials and Deals
23 July 2026
2026 Marginal zone lymphoma strategy: epidemiology, BTK biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Sézary syndrome Indication Strategy Report 2026: CCR4, Trials and Deals
23 July 2026
2026 Sézary syndrome strategy: epidemiology, CCR4 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…